NA-931 from Biomedind: A Quadruple Agonist That Could Outdo Novo Nordisk's Retatrutide Answer?

[DjJoshua]

Had to share this one,

So what exactly is NA-931 — a quadruple receptor agonist?

NA-931 stands as a first-in-class quadruple agonist targeting IGF-1, GLP-1, GIP and Glucagon receptors.

Below is the link to the listing along with everything they say it may be capable of... Perhaps the folks in China could start cranking out a knock off right away?




NA-931



NA-931 is intended for treating Diabetes, Obesity and Alcohol Use Disorder

www.biomedind.com

 

[Habibibi]

Vaporware

The Bioglutide Scam: Lies and Fraud at Biomed Industries - Aus Aminos Blog


In this piece, I'll lay out several strands of evidence for my belief that NA-931, sold under the name Bioglutide, is not real, and that Lloyd L. Tran

ausaminos.com

Why are you only learning about this now?

Why has no other company managed to bring even a dual agonist to market as an oral small molecule?

Why have you never heard of this company being involved in acquisition talks?

 

[DjJoshua]

Habibibi said:

Vaporware

View attachment 11225


The Bioglutide Scam: Lies and Fraud at Biomed Industries - Aus Aminos Blog


In this piece, I'll lay out several strands of evidence for my belief that NA-931, sold under the name Bioglutide, is not real, and that Lloyd L. Tran

View attachment 11226

ausaminos.com

Why are you only learning about this now?

Why has no other company managed to bring even a dual agonist to market as an oral small molecule?

Why have you never heard of this company being involved in acquisition talks?

On the whole, the profile resembles what you'd expect from a biotech asset in the early-to-mid stage: publicly presented Phase 2 results that look promising, trials that are registered, fresh JPM buzz for funding and exposure, plus defined next steps toward Phase 3. It hasn't been sitting idle for years with nothing to show. Should the trials pan out—particularly regarding muscle preservation—it may become a serious player in oral obesity treatment.

ClinicalTrials.gov listings

• (official U.S. registry): Several active or recently completed entries sponsored by Biomed Industries, such as:
  • NCT06564753: A Phase 2 trial in obesity/overweight with weight-related conditions (randomized, double-blind, placebo-controlled; a 13-week study assessing safety, weight loss, and more).
    
  • NCT06615700: A Phase 1 dose-escalation study examining safety, PK/PD in obese participants and T2DM patients.
    
  • NCT06732245: A Phase 2 trial evaluating NA-931 on its own or combined with tirzepatide for synergy, efficacy, safety, and muscle preservation in overweight/obese adults.These aren't just placeholders—the entries contain study designs, estimated start/completion dates (some with 2025–2026 timelines), and sponsor details.
• 
  
• Recent public updates and presentations:
  • Phase 2 topline results were presented at major 2025 conferences: ADA (June 2025), ENDO (July 2025), and EASD (September 2025).
    
  • Company press releases (through EIN Presswire and their website) from mid-2025 onward frame these as breakthroughs, claiming significant weight loss without muscle loss thanks to the IGF-1 component.
    
  • January 2026 announcements (during JPM Healthcare Week): Plans to launch two global Phase 3 programs—one as monotherapy and one in combination with semaglutide/tirzepatide for obesity, with a focus on durable weight loss and lean-mass preservation.

 

[latviantower]

DjJoshua said:

Habibibi said:

Vaporware

View attachment 11225


The Bioglutide Scam: Lies and Fraud at Biomed Industries - Aus Aminos Blog


In this piece, I'll lay out several strands of evidence for my belief that NA-931, sold under the name Bioglutide, is not real, and that Lloyd L. Tran

View attachment 11226

ausaminos.com

Why are you only learning about this now?

Why has no other company managed to bring even a dual agonist to market as an oral small molecule?

Why have you never heard of this company being involved in acquisition talks?

On the whole, the profile resembles what you'd expect from a biotech asset in the early-to-mid stage: publicly presented Phase 2 results that look promising, trials that are registered, fresh JPM buzz for funding and exposure, plus defined next steps toward Phase 3. It hasn't been sitting idle for years with nothing to show. Should the trials pan out—particularly regarding muscle preservation—it may become a serious player in oral obesity treatment.

ClinicalTrials.gov listings

• (official U.S. registry): Several active or recently completed entries sponsored by Biomed Industries, such as:
  • NCT06564753: A Phase 2 trial in obesity/overweight with weight-related conditions (randomized, double-blind, placebo-controlled; a 13-week study assessing safety, weight loss, and more).
    
  • NCT06615700: A Phase 1 dose-escalation study examining safety, PK/PD in obese participants and T2DM patients.
    
  • NCT06732245: A Phase 2 trial evaluating NA-931 on its own or combined with tirzepatide for synergy, efficacy, safety, and muscle preservation in overweight/obese adults.These aren't just placeholders—the entries contain study designs, estimated start/completion dates (some with 2025–2026 timelines), and sponsor details.
• 
  
• Recent public updates and presentations:
  • Phase 2 topline results were presented at major 2025 conferences: ADA (June 2025), ENDO (July 2025), and EASD (September 2025).
    
  • Company press releases (through EIN Presswire and their website) from mid-2025 onward frame these as breakthroughs, claiming significant weight loss without muscle loss thanks to the IGF-1 component.
    
  • January 2026 announcements (during JPM Healthcare Week): Plans to launch two global Phase 3 programs—one as monotherapy and one in combination with semaglutide/tirzepatide for obesity, with a focus on durable weight loss and lean-mass preservation.

Yep, not a peep about this since last year. Is this some kind of high-level con?

 

[Jerrey]

latviantower said:

DjJoshua said:

Habibibi said:

Vaporware

View attachment 11225


The Bioglutide Scam: Lies and Fraud at Biomed Industries - Aus Aminos Blog


In this piece, I'll lay out several strands of evidence for my belief that NA-931, sold under the name Bioglutide, is not real, and that Lloyd L. Tran

View attachment 11226

ausaminos.com

Why are you only learning about this now?

Why has no other company managed to bring even a dual agonist to market as an oral small molecule?

Why have you never heard of this company being involved in acquisition talks?

On the whole, the profile resembles what you'd expect from a biotech asset in the early-to-mid stage: publicly presented Phase 2 results that look promising, trials that are registered, fresh JPM buzz for funding and exposure, plus defined next steps toward Phase 3. It hasn't been sitting idle for years with nothing to show. Should the trials pan out—particularly regarding muscle preservation—it may become a serious player in oral obesity treatment.

ClinicalTrials.gov listings

• (official U.S. registry): Several active or recently completed entries sponsored by Biomed Industries, such as:
  • NCT06564753: A Phase 2 trial in obesity/overweight with weight-related conditions (randomized, double-blind, placebo-controlled; a 13-week study assessing safety, weight loss, and more).
    
  • NCT06615700: A Phase 1 dose-escalation study examining safety, PK/PD in obese participants and T2DM patients.
    
  • NCT06732245: A Phase 2 trial evaluating NA-931 on its own or combined with tirzepatide for synergy, efficacy, safety, and muscle preservation in overweight/obese adults.These aren't just placeholders—the entries contain study designs, estimated start/completion dates (some with 2025–2026 timelines), and sponsor details.
• 
  
• Recent public updates and presentations:
  • Phase 2 topline results were presented at major 2025 conferences: ADA (June 2025), ENDO (July 2025), and EASD (September 2025).
    
  • Company press releases (through EIN Presswire and their website) from mid-2025 onward frame these as breakthroughs, claiming significant weight loss without muscle loss thanks to the IGF-1 component.
    
  • January 2026 announcements (during JPM Healthcare Week): Plans to launch two global Phase 3 programs—one as monotherapy and one in combination with semaglutide/tirzepatide for obesity, with a focus on durable weight loss and lean-mass preservation.

Yep, not a peep about this since last year. Is this some kind of high-level con?

I'm with you on that. Issuing press releases to drum up a wave of investment money is a pretty standard play. If the rest of the trials end up confirming those pie-in-the-sky results, I'll be somewhat surprised.

 

[Lyophilized]

Already in phase I of my own "octuple" agonist receptor : GHK-Cu + KPV + BPC157 + Tirz + Reta

Joking apart, any info on new molecules is always welcome from my side

 

[Habibibi]

DjJoshua said:

Habibibi said:

Vaporware

View attachment 11225


The Bioglutide Scam: Lies and Fraud at Biomed Industries - Aus Aminos Blog


In this piece, I'll lay out several strands of evidence for my belief that NA-931, sold under the name Bioglutide, is not real, and that Lloyd L. Tran

View attachment 11226

ausaminos.com

Why are you only learning about this now?

Why has no other company managed to bring even a dual agonist to market as an oral small molecule?

Why have you never heard of this company being involved in acquisition talks?

On the whole, the profile resembles what you'd expect from a biotech asset in the early-to-mid stage: publicly presented Phase 2 results that look promising, trials that are registered, fresh JPM buzz for funding and exposure, plus defined next steps toward Phase 3. It hasn't been sitting idle for years with nothing to show. Should the trials pan out—particularly regarding muscle preservation—it may become a serious player in oral obesity treatment.

ClinicalTrials.gov listings

• (official U.S. registry): Several active or recently completed entries sponsored by Biomed Industries, such as:
  • NCT06564753: A Phase 2 trial in obesity/overweight with weight-related conditions (randomized, double-blind, placebo-controlled; a 13-week study assessing safety, weight loss, and more).
    
  • NCT06615700: A Phase 1 dose-escalation study examining safety, PK/PD in obese participants and T2DM patients.
    
  • NCT06732245: A Phase 2 trial evaluating NA-931 on its own or combined with tirzepatide for synergy, efficacy, safety, and muscle preservation in overweight/obese adults.These aren't just placeholders—the entries contain study designs, estimated start/completion dates (some with 2025–2026 timelines), and sponsor details.
• 
  
• Recent public updates and presentations:
  • Phase 2 topline results were presented at major 2025 conferences: ADA (June 2025), ENDO (July 2025), and EASD (September 2025).
    
  • Company press releases (through EIN Presswire and their website) from mid-2025 onward frame these as breakthroughs, claiming significant weight loss without muscle loss thanks to the IGF-1 component.
    
  • January 2026 announcements (during JPM Healthcare Week): Plans to launch two global Phase 3 programs—one as monotherapy and one in combination with semaglutide/tirzepatide for obesity, with a focus on durable weight loss and lean-mass preservation.

It really comes down to the top line results presentation from last year, which appears to back this up. A clinician with deep knowledge of GLP1s was at one of those conferences, sat through their presentation, and noticed multiple red flags.

Beyond that, what's the point of needing synergy with tirzepatide or semaglutide? If NA-931 truly performed that well on its own, it ought to leave both of them far behind.